OncoMatch/Clinical Trials/NCT05492123
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Is NCT05492123 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nivolumab 40 mg in 4 ml and Ipilimumab 200 MG in 40 ML for uterine cervical neoplasms.
Treatment: Nivolumab 40 mg in 4 ml · Ipilimumab 200 MG in 40 ML — A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Cervical Cancer
Disease stage
Required: Stage FIGO STAGE IB2-IB3 NODE POSITIVE, STAGE IIB-IVA (FIGO)
cervical adenocarcinoma or squamous carcinoma FIGO Stage IB2-IB3 node positive or Stage IIB-IVA
Performance status
WHO/ECOG 0–1
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: immune checkpoint inhibitor
Cannot have received: radiation therapy
Lab requirements
Blood counts
WBC ≥ 2000/μL; Neutrophil count ≥ 1500/μL; Platelet count ≥ 100 x 10^3/μL; Hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine ≤ 1.5 x ULN unless creatinine clearance ≥ 40 mL/min
Liver function
AST/ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome: < 3.0 x ULN)
WBC count (WBC) < 2000/μL ; Neutrophil count < 1500/μL; Platelet count < 100 x 103/μL; Hemoglobin level < 9.0 g/dL; Serum creatinine > 1.5 x upper limit of normal (ULN) unless creatinine clearance is ≥ 40 mL/min; AST/ALT: > 3.0 x ULN; Total bilirubin > 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of < 3.0 x ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05492123 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage FIGO STAGE IB2-IB3 NODE POSITIVE or STAGE IIB-IVA is required.
Is there an age limit?
Yes. Patients must be 95 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages